What's in Santen Pharmaceutical Co., Ltd.'s pipeline?

Santen Pharmaceutical Co., Ltd. has 14 drugs in our index: 0 marketed, 0 filed, 7 in Phase 3, 7 in Phase 2, 0 in Phase 1.

Which companies overlap with Santen Pharmaceutical Co., Ltd.'s portfolio?

Top competitors by shared drug class: Allergan, Santen Inc., GlaxoSmithKline, ANI Pharmaceuticals, Ain Shams University.

How do I subscribe to ongoing alerts?

Subscribe to /feed/company/santen-pharmaceutical-co-ltd.xml in any RSS reader. Every regulatory action and pipeline update lands in your feed.

Last reviewed 2026-05-16 · How we verify

Santen Pharmaceutical Co., Ltd. — Portfolio Competitive Intelligence Brief

Santen Pharmaceutical Co., Ltd. pipeline: 0 marketed, 0 filed, 7 Phase 3, 7 Phase 2. Recent regulatory actions, upcoming PDUFA, patent timeline, top competitor overlap.

0 marketed 0 filed 7 Phase 3 7 Phase 2 0 Phase 1 Live · 30-min refresh

Portfolio leaders (marketed + Phase 3 / filed)

Drug	Generic	Phase	Class	Target	Area
DE-111 ophthalmic solution	DE-111 ophthalmic solution	phase 3	Dopamine D1 receptor agonist	Dopamine D1 receptor	Ophthalmology
STN1013800 ophthalmic solution	STN1013800 ophthalmic solution	phase 3	Corticosteroid		Ophthalmology
DE-117B Eye Drops	DE-117B Eye Drops	phase 3	Rho kinase (ROCK) inhibitor	ROCK1/ROCK2	Ophthalmology
DE-114 ophthalmic solution	DE-114 ophthalmic solution	phase 3	Rho kinase inhibitor	ROCK (Rho-associated coiled-coil containing protein kinase)	Ophthalmology
DE-108	DE-108	phase 3	ROCK inhibitor	ROCK (Rho-associated coiled-coil-containing protein kinase)	Ophthalmology
STN1012600 ophthalmic solution 0.002%	STN1012600 ophthalmic solution 0.002%	phase 3	Corticosteroid		Ophthalmology
Tafluprost ophthalmic solution 0.0015%	Tafluprost ophthalmic solution 0.0015%	phase 3	Prostaglandin analogue	Prostaglandin F2α receptor	Ophthalmology

Therapeutic area mix

Ophthalmology · 10

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this portfolio.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this portfolio.

Patent timeline (forward window)

No upcoming patent expiries for this portfolio.

Competitive overlap (companies sharing drug classes)

Allergan · 2 shared drug classes
Santen Inc. · 2 shared drug classes
GlaxoSmithKline · 2 shared drug classes
ANI Pharmaceuticals · 1 shared drug class
Ain Shams University · 1 shared drug class
Aldeyra Therapeutics, Inc. · 1 shared drug class
Acrotech Biopharma Inc. · 1 shared drug class
AbbVie · 1 shared drug class

Subscribe to ongoing alerts

Every new pipeline event for Santen Pharmaceutical Co., Ltd.:

Cite this brief

Drug Landscape (2026). Santen Pharmaceutical Co., Ltd. — Portfolio Competitive Intelligence Brief. https://druglandscape.com/ci/company/santen-pharmaceutical-co-ltd. Accessed 2026-05-16.